Analysts at Cantor Fitzgerald pointed out the lead asset, ACR-368, a CHK1/2 inhibitor, as a candidate for Accelerated Approval in endometrial cancer potentially as early as 2026. The optimism is ...

The research team then went on to show that the PARG inhibitor can also be used in combination with other clinically accessible drugs, such as CHK1 and WEE1 inhibitors, to kill ovarian cancer cells ...

and Investigation of Isomerically Hydroxylated Indenoisoquinoline Analogues as Topoisomerase I Poisons Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell ...